Brief Summary
This study is investigating the feasibility, safety and effectiveness of delivering targeted radiation therapya treatment that uses controlled doses of radiation to damage or kill cancer cells using a device with in-built magnetic resonance (MR) imagingtests that create detailed images of areas inside the body to identify and deliver the radiation doses specifically to the prostatea walnut-shaped gland in the male reproductive system that is responsible for producing semen - a bodily fluid that acts as a vessel for sperm transport during ejaculation tumoura tissue mass that forms from groups of unhealthy cells.
Intervention/Treatment
- Stereotactic Focal Ablation.
Inclusion Criteria
- Age 40yrs or older.
- WHO performance status 0-2.
- Life expectancy at least 10 years.
- Biopsyremoval of a section of tissue to analyse for cancer cells proven adenocarcinomacancer arising from mucus-producing glands in organs of the prostate.
- Low or favourable intermediate riskthe possibility that something bad will happen prostate cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs.
- PSA less than 20 ng/mL.
- Gleason score 7.
- Clinical T stage cT1c – cT2c.
- Solitary Tumours not more than 20mm in diameter on MRI; Tumour margins visible on MRI.
- Prostate Volume less than 100cc on TRUS.
- Willing and able to give written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..